Cong Shan Li
Overview
Explore the profile of Cong Shan Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin H, Meng R, Li C, Kim S, Chai O, Lee Y, et al.
Cancer Gene Ther
. 2024 Sep;
31(11):1669-1687.
PMID: 39251779
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide, with more than 800,000 deaths each year, and its 5-year survival rate is less than 12%. The role...
2.
Wu Y, Li C, Meng R, Jin H, Chai O, Kim S
Toxicol Appl Pharmacol
. 2023 Dec;
482:116786.
PMID: 38086440
Histone deacetylase (HDAC) inhibitors diminish carcinogenesis, metastasis, and cancer cell proliferation by inducing death in cancer cells. Tissue regeneration and organ development are highly dependent on the Hippo signaling pathway....
3.
Meng R, Li C, Hu D, Kwon S, Jin H, Chai O, et al.
Korean J Physiol Pharmacol
. 2023 Aug;
27(5):493-511.
PMID: 37641811
Hippo/YAP signaling hinders cancer progression. Inactivation of this pathway contributes to the development of esophageal cancer by activation of Akt. However, the possible interaction between Akt and Hippo/YAP pathways in...
4.
Li C, Nguyen T, Chai O, Park B, Lee J, Kim S
J Oncol
. 2023 Feb;
2023:8268955.
PMID: 36785670
Gastric cancer (GC) is one of the most lethal cancers in South Korea, and it is a cancer of concern worldwide. 5-fluorouracil (5-Fu) is commonly used as the first-line therapy...